Aspirin in Reducing Events in the Elderly

Status unconfirmed · Has a placebo group

Conditions studied: Functional Disability, Dementia, Heart Disease, Stroke, Cancer, Bleeding, Depression

In brief

ASPREE-XT is a post-treatment, longitudinal observational follow-up study of ASPREE participants \[ASPREE Investigator Group, 2013; www.aspree.org; McNeil et al 2017\]. Although the ASPREE trial medication was ceased, the study activity was not stopped and ASPREE participants are continuing with scheduled visits and phone calls. An observational follow-up phase (ASPREE-XT), began in January, 2018. This will enable the monitoring of possible delayed effects of aspirin treatment, primarily on cancer incidence, metastases and mortality. In addition to monitoring the incidence of malignancy within the ASPREE cohort, the opportunity will be taken to observe any other residual effects of aspirin on the endpoints being monitored in the cohort. Continuity of contact with study participants is the key to retention of the cohort for any ongoing or future studies.

Key facts

Study ID
NCT01038583
Run by
Hennepin Healthcare Research Institute
People needed
19114
Starts
2010-01-01
Expected to finish
2024-04-01
Last updated by the study team
2021-04-05

Who can join

Age: 65 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.